FASLODEX 250 mg, solution for injection syringe, 5 ml
Active ingredients: Fulvestrant
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 5 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FASLODEX 250 mg, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intramusculaire
- Presentation description
- 1 seringue(s) préremplie(s) en verre avec aiguille(s) de 5 ml
- Marketing authorisation holder
- ASTRAZENECA AB
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Cancer du sein, dans certaines conditions précisément définies uniquement. ; JOURNAL OFFICIEL ; 14/07/05
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Jun 2004
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63545028CIP73634900CIP133400936349001Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FULVESTRANTsolution | 250 mg · 5 ml de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.